Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
167.33
+2.59 (1.57%)
At close: Aug 1, 2025, 4:00 PM
167.25
-0.08 (-0.05%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $23.74B in the quarter ending June 29, 2025, with 5.77% growth. This brings the company's revenue in the last twelve months to $90.63B, up 4.68% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$90.63B
Revenue Growth
+4.68%
P/S Ratio
4.44
Revenue / Employee
$656,242
Employees
138,100
Market Cap
402.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 43.21B |
JNJ News
- 1 day ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025) - Seeking Alpha
- 2 days ago - Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges - WSJ
- 2 days ago - Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
- 3 days ago - Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says - Forbes
- 3 days ago - Trump pressures 17 pharma CEOs to cut US drug prices - Reuters
- 3 days ago - Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days - CNBC
- 4 days ago - Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - Business Wire
- 5 days ago - Boston Jury Hits Johnson & Johnson with Record $42M Verdict in Asbestos Baby Powder Case - Business Wire